Lower urinary tract symptoms and erectile dysfunction;Sintomatología del tracto urinario inferior y disfunción eréctil

Archivos Espanoles de Urologia

Volumn 63, Issue 8, 2010, Pages 655-662

  Lavalle, Luis López Fando ^a   Almagro, Antonio Allona ^a   Bravo, Carolina Bueno ^a   Martínez, Luis Córdoba ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Erectile dysfunction; Lower urinary tract; Symptoms

Indexed keywords

ERECTILE DYSFUNCTION; HUMAN; MALE; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; PROSTATISM; REVIEW; RISK FACTOR;

ERECTILE DYSFUNCTION; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATISM; RISK FACTORS;

EID: 78149244255     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol. 2001 Aug;166(2):569-74; discussion 574-575
2. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH.Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey Eur Urol. 2003 Nov;44(5):588-94
3. Fernández Pérez C, Moreno Sierra J, Cano Escudero S, et al. Prevalence of lower urinary tract symptoms related with benign prostatic hyperplasia. Study of 1804 men aged 40 or older in Madrid. Actas Urol Esp. 2009; 33(1): 43-51
4. Darab Mehraban, Gholam Hossein Naderi, Seyed Reza Yahyazadeh, et al. Sexual Dysfunction in Aging Men with Lower Urinary Tract Symptoms. Urology, 2008: 5 (4): 260-264.
5. Berry SJ, Coffey DS, Walsh PC, et al. The development of benign prostatic hyperplasia with age. J Urol. 1984; 132: 474-479
6. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mckinlay JB. Impotence and its medical and psychosocial correlates: results of theMassachusetts Male Aging Study. J Urol. 1994; 151:54-61.
7. Pearlman CK, Kobashi LI. Frequency of intercourse in men. J Urol. 1972; 107:298-301.
8. Roberts RO, Jacobsen SJ, Rhodes T, et al. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol. 1997; 157:1711-1717.
9. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging.male (MSAM-7) Prog Urol. 2004; 14(3): 332-344
10. Moncada I. LUTS: A Risk Factor for Sexual Dysfunction in the BPH Patient. European Urology Supplements. 2003; 2:3-8.
11. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006; 97(2): 23-28
12. McVary KT, Rademaker A, Lloyd GL, et al. Autonomic nervous system overactivity in men with LUTS secondary to benign prostatic hyperplasia. J Urol 2005; 174: 1327.
13. García Cardoso J.V., López Farré A., Vela Navarrete R. Disfunción eréctil: papel del laboratorio en la evaluación diagnóstica y pronóstica. Actas Urol.Esp. 2005; 890-898.
14. Martin Morales A, Sánchez Cruz J, Saenz de Tejada I, et al. Prevalence and independent risk factors for erectile dysfunction in Spain: Results of the epidemiology of the erectile dysfunction study". J Urol, 2001; 166 (2); 569-575.
15. Martín-Morales A, Meyer G, Ramírez E. Prevalencia de disfunción eyaculatoria secundaria al tratamiento con alfa-bloqueantes en pacientes con hiperplasia benigna de próstata. Actas Urol Esp. 2008; 32 (7): 705-712.
16. Lepor H, Williford WO, Barry MJ, et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol, 1998; 160: 1358-1367.
17. Hernández Fernández C, Castaño González I, Moncada Iribarren I, Jara Rascón J, Moralejo Gárate M. Tratamiento con doxazosina en 3347 pacientes con síntomas del tracto urinario inferior. Efecto sobre su función sexual. Estudio impros. Actas Urol. Esp.2004; 290-297.
18. Moorselaar VJ. LUTS and sexual dysfunction: Implications for management of BPH. Eur Urol Supplements. 2003; 2:13-22
19. Uckert S, Oelke M, Stief CG, et al. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006; 49: 740-745
20. Sairam K, Kulinskaya E, McNicholas T, et al. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836-839
21. Mulhall JP, Guhring P, Parker M, et al. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662-667
22. Roehrborn CG, McVary KT, Kaminetsky JC, et al. The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). J Urol 2006; 175 :527.
23. Heaton J. LUTS and Sexual Dysfunction: What is the Link and How Can it Be Managed? Eur Urol Supplements. 2006; 5 :722-728.
24. Van Moorselaar RJ, Hartung R, Emberton M, et al, for the ALF-ONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005; 95: 603-608
25. Chapple CR, Wyndaele JJ, Nordling J, et al. Tamsulosin,the first prostate-selective alpha1A-adrenoceptorantagonist: a meta-analysis of two randomised, placebo-controlled, mulitcentre studies in patients withbenign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155-167
26. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998; 51: 901-906
27. Roehrborn CG, for the ALFUS Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58: 953-959
28. Hartung R, Matzkin H, Alcaraz A, et al. Age, comorbidity and antihypertensive comedication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. J Urol 2006; 175: 624-628
29. Elhilali M, Emberton M, Matzkin H, et al., for the ALF-ONE Study Group. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice. BJU Int 2005; 97: 513-519
30. McConnell JD, Roehrborn CG, Bautista OM, et al. The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398
31. Palea S, Barras M. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int 2003; 91: 873-877
32. Mayoux E, Ramirez JF, Pouyet T, et al. Alfuzosin improves penile erection triggered by apomorphine in spontaneous hypertensive rats. Eur Urol 2004; 45:110-116
33. Sciarra A. Lower Urinary Tract Symptoms (LUTS) and Sexual Dysfunction (SD): New Targets for New Combination Therapies? Eur Urol, 2007; 51: 1485-1487.
34. Tuncel A, Nalcacioglu V, Ener K, et al. Comparison of efficacy of sildenafil-only, sildenafil plus tamsulosin, and tamsulosin - only in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol Supplements. 2008; 7 (3): 171.
35. Carson CC. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int, 2006; 97(2):39-43.
36. Rosen R. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Current Opinion in Urology 2006; 16:11-19.
37. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol, 2007; 51:1717-1723
38. Kaplan SA, Reis RB, Kohn IJ. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Urol, 1998; 52 (7): 39-43.